We are live on
!
Find out more
SM
Sabby Management Portfolio holdings
AUM
$111M
1-Year Est. Return
74.4%
This Fund
S&P 500
This Quarter
Est. Return
+31.25%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$2.67B
AUM Growth
+$753M
(+39%)
Cap. Flow
-$42M
Cap. Flow
% of AUM
-1.57%
Top 10 Holdings %
Top 10 Hldgs %
54.38%
Holding
380
New
93
Increased
88
Reduced
106
Closed
73
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$10.1M |
| 2 |
CYTR
CytRx Corp
CYTR
|
+$5.67M |
| 3 |
CELG
Celgene Corp
CELG
|
+$4.08M |
| 4 |
United Therapeutics
UTHR
|
+$3.38M |
| 5 |
DVAX
Dynavax Technologies
DVAX
|
+$3.33M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sarepta Therapeutics
SRPT
|
+$7.47M |
| 2 |
Abbott
ABT
|
+$6.5M |
| 3 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$4.84M |
| 4 |
NVIV
InVivo Therapeutics Holdings Corp
NVIV
|
+$3.87M |
| 5 |
Amgen
AMGN
|
+$3.54M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 90.18% |
| 2 | Healthcare | 9.66% |
| 3 | Technology | 0.11% |
| 4 | Consumer Staples | 0.04% |
| 5 | Industrials | 0.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$803B
| $303M | 11.34% |
14,000
+5,585
| +66% | +$1.21M |
|
2
CALL
Eli Lilly
LLY
$1.01T
| $236M | 8.82% |
29,347
-774
| -3% | -$62K |
|
|
3
CALL
State Street SPDR S&P 500 ETF Trust
SPY
$803B
| $216M | 8.1% |
+10,000
| New | +$2.16M |
|
4
PUT
iShares S&P 100 ETF
OEF
$20.2B
| $185M | 6.93% |
14,892
+1,292
| +10% | +$124K |
|
|
5
PUT
Sarepta Therapeutics
SRPT
$2.16B
| $164M | 6.15% |
26,748
-2,502
| -9% | -$75.6K |
|
6
CALL
Gilead Sciences
GILD
$182B
| $92.5M | 3.47% |
+11,691
| New | +$950K |
|
7
PUT
Regeneron Pharmaceuticals
REGN
$80.5B
| $72M | 2.7% |
1,792
+632
| +54% | +$254K |
|
|
8
CALL
iShares S&P 100 ETF
OEF
$20.2B
| $67.6M | 2.53% |
+5,441
| New | +$522K |
|
9
CALL
HCA Healthcare
HCA
$92.4B
| $58.1M | 2.18% |
7,680
-1,611
| -17% | -$123K |
|
|
MON
10
CALL
DELISTED
Monsanto Co
MON
| $57.3M | 2.15% |
5,607
+273
| +5% | +$28.6K |
|
|
11
PUT
Amgen
AMGN
$206B
| $42.9M | 1.61% |
2,569
-1,373
| -35% | -$232K |
|
|
12
PUT
Eli Lilly
LLY
$1.01T
| $39.3M | 1.47% |
4,898
+7
| +0.1% | +$560 |
|
|
CELG
13
CALL
DELISTED
Celgene Corp
CELG
| $36.1M | 1.35% |
3,451
+2,756
| +397% | +$298K |
|
|
14
Sarepta Therapeutics
SRPT
$2.16B
| $32.9M | 1.23% |
536,282
-247,215
| -32% | -$7.47M |
|
|
15
Regeneron Pharmaceuticals
REGN
$80.5B
| $30.5M | 1.14% |
75,919
+4,394
| +6% | +$1.76M |
|
|
16
CALL
Bristol-Myers Squibb
BMY
$130B
| $29.2M | 1.09% |
+5,409
| New | +$347K |
|
17
CALL
Alkermes
ALKS
$7.71B
| $28.2M | 1.06% |
3,249
+1,914
| +143% | +$91K |
|
18
CALL
Merck
MRK
$357B
| $28M | 1.05% |
+4,702
| New | +$275K |
|
19
CALL
AbbVie
ABBV
$454B
| $26.1M | 0.98% |
4,136
-13,871
| -77% | -$898K |
|
|
CELG
20
PUT
DELISTED
Celgene Corp
CELG
| $25.2M | 0.95% |
2,415
+2,338
| +3,036% | +$253K |
|
21
CALL
Acadia Healthcare
ACHC
$2.64B
| $24.8M | 0.93% |
+7,784
| New | +$405K |
|
|
22
Amgen
AMGN
$206B
| $22.2M | 0.83% |
133,176
-20,906
| -14% | -$3.54M |
|
23
CALL
Agios Pharmaceuticals
AGIO
$2.01B
| $21.7M | 0.81% |
+4,108
| New | +$179K |
|
|
24
CALL
Sarepta Therapeutics
SRPT
$2.16B
| $21.7M | 0.81% |
3,526
-11,699
| -77% | -$354K |
|
|
25
PUT
Abbott
ABT
$176B
| $21.1M | 0.79% |
5,000
| – | – |
|
Similar funds
IWA
BFA
WPWM
BCM
ZS
KC
FI
CIM
Sabby Management's Q3 2016 Portfolio in Review
As of Q3 2016, Sabby Management held 380 positions worth $2.67B, up 39% from $1.92B the previous quarter. Its ten largest holdings account for 54% of the portfolio.
Sabby Management's Q3 2016 filing shows 93 new, 88 increased, 106 reduced and 73 closed positions. Its largest new stake was Bristol-Myers Squibb: 156,887 shares worth $8.46M. The largest sale was Sarepta Therapeutics, an estimated $7.47M.
By sector, the portfolio is most concentrated in Miscellaneous at 90% of assets, up from 86% a quarter earlier, followed by Healthcare and Technology.
- Sabby Management's largest Q3 2016 buy was Bristol-Myers Squibb: 156,887 shares worth $8.46M.
- Sabby Management added most to Dynavax Technologies in Q3 2016, an estimated $3.33M increase.
- Sabby Management's biggest Q3 2016 reduction was Sarepta Therapeutics, cutting an estimated $7.47M.
- Sabby Management fully exited Global Blood Therapeutics, Inc. in Q3 2016, selling an estimated $4.84M.
- Sabby Management's ten largest holdings make up 54% of its $2.67B portfolio in Q3 2016.
- Sabby Management opened 93 new positions and closed 73 in Q3 2016.
- Sabby Management's portfolio value rose 39% quarter-over-quarter to $2.67B.
Based on Sabby Management's 13F filing for Q3 2016, filed 14 Nov 2016.